Rice Hall James & Associates LLC Acquires 674,403 Shares of Amicus Therapeutics, Inc. $FOLD

Rice Hall James & Associates LLC boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,434,717 shares of the biopharmaceutical company’s stock after purchasing an additional 674,403 shares during the period. Amicus Therapeutics accounts for approximately 1.5% of Rice Hall James & Associates LLC’s holdings, making the stock its 19th largest holding. Rice Hall James & Associates LLC’s holdings in Amicus Therapeutics were worth $27,066,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co increased its stake in shares of Amicus Therapeutics by 2.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 2,263 shares in the last quarter. Osaic Holdings Inc. lifted its position in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 3,677 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Amicus Therapeutics by 5.9% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 66,238 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 3,688 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Amicus Therapeutics in the first quarter worth about $30,000.

Insider Activity

In other Amicus Therapeutics news, insider Jeff Castelli sold 76,158 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.16, for a total value of $773,765.28. Following the completion of the transaction, the insider directly owned 439,318 shares of the company’s stock, valued at approximately $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer owned 1,129,782 shares of the company’s stock, valued at $12,269,432.52. This trade represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 345,450 shares of company stock worth $3,657,000 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $14.25 on Friday. The stock has a market cap of $4.40 billion, a PE ratio of -356.16 and a beta of 0.46. The stock has a 50-day moving average of $10.08 and a 200-day moving average of $8.11. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. As a group, sell-side analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. The Goldman Sachs Group increased their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday. TD Cowen lowered Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective on the stock. in a research report on Monday, December 22nd. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.81.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.